OOIR: Observatory of International Research

Papers

(The TQCC of Journal of the American College of Cardiology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019	4569
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up	2111
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic	1281
Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic	881
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease	854
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure	817
Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19	730
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction	595
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization	567
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary	539
Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection	522
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement	522
Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research	442
The Global Burden of Cardiovascular Diseases and Risk	405
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy	370
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19	358
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation	349
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain	344
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary	334
Preeclampsia—Pathophysiology and Clinical Presentations	313
Cardiac Troponin for Assessment of Myocardial Injury in COVID-19	309
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations	304
Worldwide Prevalence of Familial Hypercholesterolemia	303
Characterization of Myocardial Injury in Patients With COVID-19	288
Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic	286

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction	280
The Global Burden of Cardiovascular Diseases and Risks	274
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes	273
Virtual Learning During the COVID-19 Pandemic	268
Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation	250
Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic	248
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease	248
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care	241
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19	225
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies	222
2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Pl	222
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases	218
Spontaneous Coronary Artery Dissection	217
Management of Acute Myocardial Infarction During the COVID-19 Pandemic	215
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease	215
Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality	212
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy	212
High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction	210
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk	205
Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation	204
The ARIC (Atherosclerosis Risk In Communities) Study	200
Machine Learning and the Future of Cardiovascular Care	197
Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy	194
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants	193
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis	191
Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation	182
Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States	180
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women	175
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction	174
Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis	174
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy	171
Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China	168
Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves	166
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy	164
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease	164
Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk	162
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk	161
Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia	160
Heart Failure With Recovered Left Ventricular Ejection Fraction	155
Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis	154
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary	154
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary	152
Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19	152
Cardiovascular Deaths During the COVID-19 Pandemic in the United States	151
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients	149
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia	147
Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation	147
Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI	145
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients	144
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19	144

2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or Wi	143
Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement	140
Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies	139
Management of Hypertrophic Cardiomyopathy	134
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy	133
Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis	132
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease	131
Pathophysiology of Takotsubo Syndrome	131
2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation	130
International Impact of COVID-19 on the Diagnosis of Heart Disease	130
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis	129
Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-Study	128
Interventions for Frailty Among Older Adults With Cardiovascular Disease	127
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque	126
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy	125
Presentation and Outcome of Arrhythmic Mitral Valve Prolapse	122
Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial	122
Dietary Inflammatory Potential and Risk of Cardiovascular Disease Among Men and Women in the U.S.	121
Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction	121
Cardiac Involvement in Fabry Disease	119
Challenges in Cardiac and Pulmonary Sarcoidosis	119
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation	119
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System	118
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure	118
Inflammation, Aging, and Cardiovascular Disease	118
Ticagrelor With or Without Aspirin After Complex PCI	117
Prevalence and Prognostic Significance of Malnutrition in Patients With Acute Coronary Syndrome	116
Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial	116
Global Chronic Total Occlusion Crossing Algorithm	116
Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease	114
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis	113
Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury	113
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction	113
Smartphone Activation of Citizen Responders to Facilitate Defibrillation in Out-of-Hospital Cardiac Arrest	112
Epicardial Adipose Tissue Accumulation Confers Atrial Conduction Abnormality	112
Medial Arterial Calcification	112
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial	111
Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States	110
Associations Between Cardiovascular Risk, Structural Brain Changes, and Cognitive Decline	110
Short-Term Exposure to Ambient Air Pollution and Mortality From Myocardial Infarction	110
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair	109
Cardiac Rehabilitation for Patients With Heart Failure	108
Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events	107
Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion	107
VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins	107
Type A Aortic Dissection—Experience Over 5 Decades	106
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study	106
Sleep Disordered Breathing and Cardiovascular Disease	105
Mitochondria-Rich Extracellular Vesicles From Autologous Stem Cell–Derived Cardiomyocytes Restore Energetics of Ischemic Myocardium	105
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure	105
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction	103
Association of Clonal Hematopoiesis With Incident Heart Failure	102
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers	102
ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak	101
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis	98
Coronary 18F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease	98
Transcatheter Mitral Valve Therapy in the United States	97
Safety of Transesophageal Echocardiography to Guide Structural Cardiac Interventions	96
Takotsubo Cardiomyopathy in COVID-19	96
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams	96
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload	96
Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement	95
Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017	95
2020 ACC Expert Consensus Decision Pathway on Management of Conduction Disturbances in Patients Undergoing Transcatheter Aortic Valve Replacement	95
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia	94
Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers	94
Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis	93
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)	93
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension	92
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment	92
Abnormalities of Potassium in Heart Failure	91
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates	91
Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation	90
Initial Findings From the North American COVID-19 Myocardial Infarction Registry	90
Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease	90
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants	90
Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021	90
Kidney Function and Outcomes in Patients Hospitalized With Heart Failure	89
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction	88
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice	88

2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation	87
Triglycerides and Residual Atherosclerotic Risk	87
Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19	86
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction	85
Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy	84
Criteria for Defining Stages of Cardiogenic Shock Severity	83
Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum	83
Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease	82
Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy	82
Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction	81
Managing Atherosclerotic Cardiovascular Risk in Young Adults	80
Criteria for Iron Deficiency in Patients With Heart Failure	79
Coronary In-Stent Restenosis	78
Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians	78
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia	78
Myocardial Bridging: Diagnosis, Functional Assessment, and Management	77
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes	77
Renal Denervation in High-Risk Patients With Hypertension	77
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF	77
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis	77
Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization	76
Practice Changes at U.S. Transplant Centers After the New Adult Heart Allocation Policy	76
High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated COVID-19 Patients	75
International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19	75
Association of Lipoprotein(a) With Atherosclerotic Plaque Progression	74
Pulmonary Hypertension in HFpEF and HFrEF	74
Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality	74
Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization	73
Physiological Stratification of Patients With Angina Due to Coronary Microvascular Dysfunction	73
Propensity-Matched Comparison of the Ross Procedure and Prosthetic Aortic Valve Replacement in Adults	72
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF	72
Heart Failure With Preserved Ejection Fraction	72
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants	72
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol	72
Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality	71
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes	71
Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function	71
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure	71
Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, and Sex	71
Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations	71
The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation	70
Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure	70
Prospective Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19	70
Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease	70
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary	69
Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease	68
Cardiovascular Disease Risk Among Cancer Survivors	68
Impact of Tricuspid Regurgitation on Clinical Outcomes	68
Complicated Carotid Artery Plaques as a Cause of Cryptogenic Stroke	68
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk	68
Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension	67
Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure	67
Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death	67
Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses	67
Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States	67
Pericardial Fat and the Risk of Heart Failure	65
Diet-Derived Circulating Antioxidants and Risk of Coronary Heart Disease	65
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome	65
Cardiovascular Risk in Patients With Psoriasis	65
Discrepancies in Measurement of the Thoracic Aorta	65
Gerotechnology for Older Adults With Cardiovascular Diseases	64
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy	64
Increasing Participation of Women in Cardiovascular Trials	64
Long-Term Outcomes of Patients Undergoing the Ross Procedure	64
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)	64
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol	63
Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis	63
Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction	63
Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy	63
Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With Hypertensive Disorders of Pregnancy	62
Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement	62
Hypertensive Disorders of Pregnancy and Subsequent Risk of Premature Mortality	62
Managing Patients With Short-Term Mechanical Circulatory Support	61
African-American COVID-19 Mortality	61
Machine Learning Assessment of Left Ventricular Diastolic Function Based on Electrocardiographic Features	61
Cryoballoon Ablation as Initial Treatment for Atrial Fibrillation	61
Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4	61
Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation	61
Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease	60
Optimum Blood Pressure in Patients With Shock After Acute Myocardial Infarction and Cardiac Arrest	60
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction	60
Infective Endocarditis After Transcatheter Aortic Valve Replacement	60
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome	60
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy	60
Classification of Heart Failure According to Ejection Fraction	60
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention	59
Acute Myocardial Injury at Hospital Admission Is Associated With All-Cause Mortality in COVID-19	59
Acute Aortic Syndrome Revisited	59
Moderate Aortic Stenosis in Patients With Heart Failure and Reduced Ejection Fraction	59
Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease	59
Reliability of Office, Home, and Ambulatory Blood Pressure Measurements and Correlation With Left Ventricular Mass	59
Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging	58
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy	58
Progression of Early Subclinical Atherosclerosis (PESA) Study	58
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy	58